For these reasons, as well as decreased cost of testing multiple genes via next-generation sequencing (NGS) panel GT, patients suspected to have LS based on tumor GT are now frequently offered sequencing and deletion/duplication analysis of all LS-related genes, MSH2 inversion analysis, and deletion/duplication analysis of EPCAM. Therefore, updated comprehensive GT for LS or additional hereditary CRC predisposition syndromes may be appropriate for individuals who previously had incomplete GT. The gene discussed is MSH2; the disease is neoplasm.